T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Search
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Netherton syndrome (NS)
Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
Facts about the INPULSIS™ trials
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.